How Much Does Superficial Radiation Therapy (SRT) Cost?

Superficial radiation therapy for nonmelanoma skin cancer can range from roughly $465 to well over $10,000 per treated lesion, depending on whether you receive standard office-based SRT or the newer image-guided version, and how many treatment sessions your plan calls for. That enormous spread surprises most people, because the phrase “office-based radiation” sounds like it should have a single, predictable price tag. In practice, the total bill is shaped by the technology used, the number of fractions prescribed, the complexity of treatment planning, and whether your insurance or Medicare covers each component.

Baseline Reimbursement for Office-Based SRT

The most straightforward cost figures come from Medicare reimbursement data for dermatology-office SRT. A course of five fractions reimburses at about $465, while a twelve-fraction course comes in around $636. Those numbers bundle together the treatment simulation, dosimetry (the radiation dose calculation), and actual delivery of each session.¹ For a straightforward basal cell carcinoma on the trunk that only needs a handful of sessions, these figures represent the lower end of what SRT costs the healthcare system.

Keep in mind that reimbursement rates reflect what Medicare pays, not necessarily what you see on a bill before insurance adjustments. If you are uninsured or out of network, the facility charge can be higher. Still, the Medicare figures are a useful baseline because most SRT for skin cancer is performed on older adults who are Medicare-eligible, and many private insurers benchmark their own rates off the Medicare fee schedule.

Why the Number of Sessions Matters So Much

SRT is delivered in fractions, meaning you come in multiple times rather than getting one large dose. The total cost scales almost linearly with those visits. A five-fraction course costs less than half of what a twelve-fraction course does, and some treatment plans call for even more sessions. For squamous cell carcinomas, a commonly recommended regimen involves up to 25 sessions, and at that volume the cumulative charges climb quickly.

The fraction count depends on the tumor type, its size, its location, and the prescribing physician’s protocol. A small basal cell carcinoma on the back of the hand might be treated in five to eight sessions, while a larger or more aggressive squamous cell carcinoma on the face could require 20 or more. There is no single “standard” number. This variability is one reason cost estimates for SRT range so widely: two patients with the same diagnosis can end up on very different treatment schedules.

Image-Guided SRT and the Cost Premium

A newer variant called image-guided superficial radiation therapy, or IGSRT, uses ultrasound imaging to visualize the tumor before each fraction. The idea is to verify the treatment field in real time, which can improve targeting accuracy. But this technology adds substantially to the bill. A modeled cost analysis comparing IGSRT to Mohs micrographic surgery found that a 10-session IGSRT regimen ranged from about $1,450 to $10,245, while a 25-session regimen ranged from roughly $2,059 to $25,511.²

Those upper-end numbers are startling. The wide ranges reflect differences in how many billable components are included in each session. The actual delivery of the radiation beam accounts for only about 3.74% of the per-session cost. The rest comes from treatment planning, simulation, dosimetry calculations, and the image-guidance component itself.² In other words, the expensive part of SRT is not the radiation; it is everything that surrounds it.

Whether image guidance is necessary for a given lesion is a clinical judgment call that also happens to be a financial one. For straightforward, well-defined tumors, standard SRT without imaging may work just as well and cost a fraction of the price. If your provider recommends IGSRT, it is reasonable to ask what clinical advantage the imaging adds in your specific case.

How SRT Compares to Mohs Surgery

Mohs micrographic surgery is the most common treatment for nonmelanoma skin cancers, especially on the face. Its cost typically falls between about $1,010 and $1,567, depending on the location and the type of wound repair required.² That is a single-day procedure, meaning the patient shows up once, has the cancer removed in stages, and goes home with the wound closed.

By comparison, even a modest IGSRT regimen of 10 sessions can exceed that range, and a full 25-session course can run dramatically higher. One analysis found that SRT could be anywhere from 1.1 to nearly 23 times more expensive than Mohs, regardless of how complex the surgical repair would have been.² A separate analysis using the CMS provider and service data set reached a similar conclusion, finding that superficial radiation therapy costs exceeded those of Mohs surgery for nonmelanoma skin cancer treatment.³

That comparison sounds damning for SRT on a pure cost basis. But comparing a multi-visit radiation course to a single-visit surgery only on sticker price misses a few things. Mohs carries its own downstream expenses: wound care supplies, medications for pain, possible debridement, and in some cases reconstruction using grafts, which can add significantly to the bill.⁴ Those surgical follow-up costs do not always show up in the initial comparison.

Indirect Costs You Might Not Expect

The sticker price of any radiation course understates the real cost to the patient. Every fraction requires a clinic visit, which means transportation, parking, and time out of your day. Over 10 to 25 sessions, those costs pile up. A cost comparison of radiation therapy versus topical treatment for a related skin condition illustrated this clearly: travel-related costs for the radiation group were estimated at about 7.5 times higher than the comparison group, and the total societal cost (including productivity loss for patients who were still working) was roughly $4,379 for the radiation group versus around $698 for the topical group.⁵

Those figures come from a study of radiation therapy for lentigo maligna rather than standard nonmelanoma skin cancer, and they reflect an Australian healthcare setting, so the dollar amounts will not map exactly to an American patient’s experience. But the pattern is consistent: repeated clinic visits generate real costs that insurance does not cover and that rarely appear in published cost-effectiveness analyses. If you live far from the treating clinic, rely on ride services, or lose wages each time you miss work, the indirect burden of a 20-session SRT course can rival the treatment charges themselves.

This is one of the hidden trade-offs when choosing SRT over surgery. Mohs requires one visit (sometimes two if the wound closure is staged). SRT requires many. For a retired person who lives near the clinic and does not mind the trips, the convenience gap may be small. For someone who is still employed and has to drive an hour each way, it can be enormous.

Insurance and Medicare Coverage

SRT for nonmelanoma skin cancer is generally covered by Medicare and most private insurers, since it is an established treatment with recognized billing codes. The procedure is typically performed in a dermatologist’s office rather than a hospital radiation department, and the billing codes include simulation, dosimetry, and per-fraction delivery. IGSRT is also often covered by insurance, which has helped its adoption in outpatient dermatology settings.⁴

Coverage, though, does not mean zero out-of-pocket cost. Under Medicare Part B, you typically pay 20% of the approved amount after meeting your deductible. For a 12-fraction standard SRT course reimbursed at around $636, that co-insurance might only be about $127. For a 25-session IGSRT course billed in the thousands, your 20% share could be much more significant. If you have supplemental insurance (Medigap), it may pick up some or all of that remainder, but that depends on your plan.

Private insurance plans vary widely. Some may require prior authorization for radiation therapy, especially when surgery is available as an alternative. If SRT is recommended because you are not a good surgical candidate (due to blood-thinning medication, advanced age, or a tumor in a location where surgery would be disfiguring), the insurer is more likely to approve it without pushback. If SRT is simply your preference over surgery, you may face more scrutiny.

When SRT Is Recommended Despite Higher Cost

Given the cost disadvantage relative to Mohs, you might wonder why SRT exists at all. The answer has less to do with economics and more to do with who the patient is. SRT is considered a safe and effective first-line radiation option for basal cell and squamous cell carcinomas, and published consensus guidelines endorse it for patients who are not ideal surgical candidates.⁶ That includes elderly patients with multiple medical problems that make anesthesia risky, people on anticoagulants where bleeding during surgery is a concern, and patients with tumors in cosmetically sensitive areas where surgical excision would leave noticeable scars or require complex reconstruction.

For those groups, the relevant comparison is not “SRT versus a smooth Mohs surgery” but “SRT versus a Mohs surgery complicated by poor healing, infection risk, or a graft.” Once surgical complications enter the picture, the cost gap narrows or even reverses. A straightforward Mohs procedure on a healthy 55-year-old is hard to beat on cost. A Mohs procedure on an 88-year-old taking blood thinners, followed by a skin graft that does not heal well, is a different calculation entirely.

SRT also plays a role in treating recurrent keloids after surgical excision, where it significantly reduces the chance that the keloid comes back.⁷ In that context, cost is weighed against the expense and frustration of repeated surgeries for a scar that keeps returning.

What Drives the Wide Price Ranges

The gap between a $465 SRT course and a $25,000 IGSRT course is not explained by a single variable. Several factors stack on top of each other:

Technology tier: Standard SRT uses a fixed-energy X-ray beam and minimal imaging. IGSRT adds ultrasound guidance before each session, which introduces additional billing codes and equipment costs.
Number of fractions: Five sessions cost less than 25. The prescribing protocol depends on tumor characteristics and physician preference, and there is no universal standard for how many fractions are “enough.”
Billing components per session: Each visit can generate charges for treatment delivery, treatment management, dosimetry review, and (for IGSRT) image guidance. The delivery itself represents under 4% of the per-session cost; the planning and management charges dominate.
Facility versus office setting: SRT delivered in a hospital outpatient department is generally billed at higher rates than the same treatment in a dermatologist’s private office, due to the way facility fees work under Medicare.
Geographic variation: Medicare reimbursement rates are adjusted by locality. A procedure reimbursed at one rate in rural Mississippi may be reimbursed at a meaningfully different rate in Manhattan, because the geographic practice cost index accounts for local wages, rent, and malpractice costs.

Understanding which of these factors apply to your situation is the key to predicting your actual cost. A patient getting standard SRT in a dermatology office for a small basal cell carcinoma on the arm, with five fractions, is at the cheap end of the spectrum. A patient getting 25-session IGSRT in a hospital outpatient department for a facial squamous cell carcinoma is at the expensive end. Most people fall somewhere in between.

Questions to Ask Before Starting Treatment

If SRT has been recommended for you, a few questions can help you anticipate what you will actually pay. Ask your provider how many fractions the treatment plan involves, and whether image guidance will be used. Request a predetermination from your insurance company, which is a written confirmation of what they will cover before treatment starts. Ask the billing department for an estimate that includes all components: simulation, dosimetry, each fraction’s delivery charge, and any management fees. If the total seems high, ask whether a shorter-fraction protocol is clinically appropriate for your tumor type. Some evidence suggests that fewer fractions at higher doses per session (called hypofractionation) can be effective for certain lesions, and fewer visits mean lower total charges and less time spent traveling to the clinic.

It is also worth asking whether the treating facility is billing as a physician office or as a hospital outpatient department, since the latter carries higher facility fees. If you have a choice between two providers offering SRT, and one is hospital-affiliated while the other is a freestanding dermatology office, the office setting will generally be cheaper for the same treatment.

SRT for Keloids and Non-Cancer Uses

Most discussions of SRT cost focus on skin cancer, but SRT is also used to prevent keloid recurrence after surgical excision. Keloids are raised, thickened scars that grow beyond the boundary of the original wound, and they have a frustrating tendency to come back after removal. Applying SRT to the excision site in the days following surgery substantially lowers the recurrence rate.⁶

Keloid SRT courses tend to be shorter than cancer courses, often three to six fractions delivered over a few days. That puts them at the lower end of the SRT cost range. However, insurance coverage for keloid treatment is less predictable than for cancer. Some insurers classify keloid treatment as cosmetic, particularly if the keloid is not causing pain or functional impairment. If coverage is denied, you may be looking at the full out-of-pocket cost, which for a short course in a dermatology office could be in the range of a few hundred to around a thousand dollars based on the per-fraction reimbursement rates discussed earlier. It is worth confirming coverage before scheduling, because an appeal after denial can delay treatment and reduce the effectiveness of post-excision radiation, which works best when started within 24 to 72 hours of surgery.

The Accessibility Argument

One aspect of SRT that cost analyses sometimes overlook is access. Mohs surgery requires a fellowship-trained Mohs surgeon, and those specialists are concentrated in urban and suburban areas. Patients in rural regions may face long drives to reach one, plus the cost of overnight stays if the surgery requires a next-day wound check. SRT, by contrast, can be administered by qualified radiation therapists under physician oversight, and the equipment fits in a standard dermatology office.⁴ For a patient who would otherwise need to travel three hours to the nearest Mohs surgeon, having SRT available locally changes the real-world cost equation even if the sticker price is higher on paper.

There is also a quality-of-life dimension that does not show up on a bill. SRT avoids surgical wounds, stitches, and scars. For tumors on the nose, eyelids, ears, or lips, where Mohs surgery can be disfiguring even when expertly performed, the cosmetic benefit of radiation may matter to patients in ways that a pure cost comparison cannot capture. The trade-off is real: you pay more in visits and possibly in dollars, but you avoid a wound that takes weeks to heal and a scar that lasts a lifetime.

1
PubMed Central. Recommendations for Cost-Conscious Treatment of Basal Cell Carcinoma
2
PubMed. Modeled Cost Analysis Using CPT/Medicare Rates and Approach Comparing Superficial Radiation Therapy Versus Mohs in Patients With Squamous Cell Carcinoma
3
Journal of the American Academy of Dermatology. The costs of superficial radiation therapy are greater than Mohs micrographic surgery for the treatment of nonmelanoma skin cancer
4
PubMed Central. Analysis of image-guided superficial radiation therapy (IGSRT) on the treatment of early-stage non-melanoma skin cancer (NMSC) in the outpatient dermatology setting
5
Journal of the American Academy of Dermatology. A cost comparison of radiotherapy and topical imiquimod for lentigo maligna treatment: Considerations for clinical decision-making
6
PubMed Central. Consensus Guidelines on the Use of Superficial Radiation Therapy for Treating Nonmelanoma Skin Cancers and Keloids
7
Journal of Clinical and Aesthetic Dermatology. Consensus Guidelines on the Use of Superficial Radiation Therapy for Treating Nonmelanoma Skin Cancers and Keloids